Herbers, E., Patrikoski, M., Wagner, A., Jokinen, R., Hassinen, A., Heinonen, S., Miettinen, S., Peltoniemi, H., Pirinen, E., & Pietiläinen, K. H. (2022). Preventing white adipocyte browning during differentiation in vitro: The effect of differentiation protocols on metabolic and mitochondrial phenotypes. Stem Cells International, 2022, 1–21. https://doi.org/10.1155/2022/3308194
Preventing white adipocyte browning during differentiation in vitro : the effect of differentiation protocols on metabolic and mitochondrial phenotypes
|Author:||Herbers, Elena1; Patrikoski, Mimmi1; Wagner, Anita2,3;|
1Obesity Research Unit, Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland
2Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland
3Research Unit for Internal Medicine, Faculty of Medicine, University of Oulu, FIN-90220 Oulu, Finland
4Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
5Adult Stem Cells Group, Faculty of Medicine and Health Technologies, Tampere University, Tampere, Finland
6Research, Development and Innovation Center, Tampere University Hospital, Tampere, Finland
7Tilkka Hospital, Helsinki, Finland
8Obesity Center, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
|Online Access:||PDF Full Text (PDF, 4.7 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2022093060495
|Publish Date:|| 2022-09-30
Mitochondrial dysfunction in white adipose tissue is strongly associated with obesity and its metabolic complications, which are important health challenges worldwide. Human adipose-derived stromal/stem cells (hASCs) are a promising tool to investigate the underlying mechanisms of such mitochondrial dysfunction and to subsequently provide knowledge for the development of treatments for obesity-related pathologies. A substantial obstacle in using hASCs is that the key compounds for adipogenic differentiation in vitro increase mitochondrial uncoupling, biogenesis, and activity, which are the signature features of brown adipocytes, thus altering the white adipocyte phenotype towards brown-like cells. Additionally, commonly used protocols for hASC adipogenic differentiation exhibit high variation in their composition of media, and a systematic comparison of their effect on mitochondria is missing. Here, we compared the five widely used adipogenic differentiation protocols for their effect on metabolic and mitochondrial phenotypes to identify a protocol that enables in vitro differentiation of white adipocytes and can more faithfully recapitulate the white adipocyte phenotype observed in human adipose tissue. We developed a workflow that included functional assays and morphological analysis of mitochondria and lipid droplets. We observed that triiodothyronine- or indomethacin-containing media and commercially available adipogenic media induced browning during in vitro differentiation of white adipocytes. However, the differentiation protocol containing 1 μM of the peroxisome proliferator-activated receptor gamma (PPARγ) agonist rosiglitazone prevented the browning effect and would be proposed for adipogenic differentiation protocol for hASCs to induce a white adipocyte phenotype. Preserving the white adipocyte phenotype in vitro is a crucial step for the study of obesity and associated metabolic diseases, adipose tissue pathologies, such as lipodystrophies, possible therapeutic compounds, and basic adipose tissue physiology.
Stem cells international
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
1182 Biochemistry, cell and molecular biology
This work was supported by the Academy of Finland 335443, 314383, 266286, and 314455); Academy of Finland Profi6 (336449); Academy of Finland, Centre of Excellence in Research on Mitochondria, Metabolism and Disease (Fin-MIT) (272376); Finnish Medical Foundation; Gyllenberg Foundation; Novo Nordisk Foundation (NNF20OC0060547,NNF17OC0027232, and NNF10OC1013354); Finnish Diabetes Research Foundation; Finnish Foundation for Cardiovascular Research; University of Helsinki and Helsinki University Hospital; Government Research Funds, Orion Research Foundation, and Paulo Foundation; and Finnish Medical Foundation TERVA funding.
© 2022 Elena Herbers et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.